Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers
Surveillance practices differed among participating centers and often do not align with the current guideline. A consensus based consistent approach would benefit both patients and physicians.
Authors
- Anja Gesierich
- Andrea Forschner (ORCID: https://orcid.org/0000-0002-6185-4945)
- Konstantin Drexler (ORCID: https://orcid.org/0009-0004-6601-6299)
- Friedegund Meier (ORCID: https://orcid.org/0000-0003-4340-9706)
- Lucie Heinzerling (ORCID: https://orcid.org/0000-0002-9074-8017)
- Max Schlaak (ORCID: https://orcid.org/0000-0002-1663-8098)
- Elisabeth Livingstone (ORCID: https://orcid.org/0000-0001-8279-9239)
- Frank Meiß (ORCID: https://orcid.org/0000-0002-4044-9094)
- Markus Reitmajer (ORCID: https://orcid.org/0000-0002-7134-1043)
- Lisa Zimmer (ORCID: https://orcid.org/0000-0002-3680-3521)
- Markus V. Heppt (ORCID: https://orcid.org/0000-0003-4603-1825)
- Kai‐Martin Thoms
Institutions
- University of Freiburg (DE)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- LMU Klinikum (DE)
- University Hospital Regensburg (DE)
- Humboldt-Universität zu Berlin (DE)
- Universitätsklinikum Erlangen (DE)
- National Center for Tumor Diseases (DE)
- Nephrologisches Zentrum Goettingen (DE)
- Essen University Hospital (DE)
- Universitätsklinikum Würzburg (DE)
- Comprehensive Cancer Center Erlangen (DE)
- University Hospital Carl Gustav Carus (DE)
- Technische Universität Dresden (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- JDDG Journal der Deutschen Dermatologischen Gesellschaft
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1111/ddg.15963
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Les Laboratories Pierre Fabre
- Galderma
- Sun Pharma
- Sanofi Genzyme